Differential effects of high-dose amisulpride versus flupentixol on latent dimensions of depressive and negative symptomatology in acute schizophrenia: An evaluation using confirmatory factor analysis

International Clinical Psychopharmacology

Volumn 17, Issue 5, 2002, Pages 249-261

  Müller, Matthias J ^a   Wetzel, H ^a   Benkert, O ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Amisulpride; Antipsychotics; Confirmatory factor analysis; Depression; Flupentixol; Schizophrenia

Indexed keywords

AMISULPRIDE; BIPERIDEN; CHOLINERGIC RECEPTOR BLOCKING AGENT; DIAZEPAM; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; FLUOXETINE; FLUPENTIXOL; IMIPRAMINE; NEUROLEPTIC AGENT; SEROTONIN 2 ANTAGONIST;

ACUTE PSYCHOSIS; ADULT; AGED; AKINESIA; ANHEDONIA; APATHY; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SELECTIVITY; DRUG TOLERABILITY; EXPERIMENTAL MODEL; EXTRAPYRAMIDAL SYMPTOM; FACTORIAL ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEGATIVE SYNDROME; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 0036738135     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200209000-00005     Document Type: Article

References (78)

1. Addington D, Addington J, Maticka-Tysdale E, Joyce J (1992) Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res 6:201-208.
2. Amore M, Jori MC (2001) Faster response on amisulpride 50 mg versus sertraline 50-100 mg in patients with dysthymia or double depression: a randomized, double-blind, parallel group study. Int Clin Psychopharmacol 16:317-324.
3. Andreasen NC (1983) The Scale for the Assessment of Negative Symptoms (SANS). Iowa City, IA: University of Iowa.
4. Andreasen NC (2000) Schizophrenia: the fundamental questions. Brain Res Brain Res Rev 31:106-112.
5. Andreasen NC, Arndt S, Alliger R, Miller D, Flaum M (1995) Symptoms of schizophrenia. Methods, meanings and mechanisms. Arch Gen Psychiatry 52:341-351.
6. Awad AG, Voruganti LN, Heslegrave RJ, Hogan TP (1996) Assessment of the patient's subjective experience in acute neuroleptic treatment: implications for compliance and outcome. Int Clin Psychopharmacol 11(Suppl. 2):55-59.
7. Barnes TRE (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676.
8. Barnes TRE, Curson DA, Liddle PF, Patel M (1989) The nature and prevalence of depression in chronic schizophrenic in-patients. Br J Psychiatry 154:486-491.
9. Bech P (1981) Rating Scales for affective disorders: Their validity and consistency. Acta Psychiat Scand 64(Suppl. 295):1-101.
10. Bech P, Rafaelsen OJ (1980) The use of rating scales exemplified by a comparison of the Hamilton and the Bech-Rafaelsen Melancholia Scale. Acta Psychiat Scand 62(Suppl. 285):128-131.
11. Bell MD, Lysaker PH, Beam-Goulet JL, Milstein RM, Lindenmayer JP (1994) Five-component model of schizophrenia: Assessing the factorial invariance of the positive and negative syndrome scale. Psychiatry Res 52:295-303.
12. Bentler PM (1995) EQS: Structural Equations Program Manual. Encino, CA: Multivariate Software Inc.
13. Birchwood M, Mason R, MacMillan F, Healy J (1993) Depression, demoralization and control over psychotic illness: a comparison of depressed and non-depressed patients with a chronic psychosis. Psychol Med 23: 387-395.
14. Bollen KA, Long JS (1993) Testing Structural Equation Models. Newbury Park, CA: Sage.
15. Bustamante S, Maurer K, Löffler W, Häfner H (1994) Depression im Frühverlauf der Schizophrenie. Fortschr Neurol Psychiat 62:317-329.
16. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, et al. (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87-96.
17. Cassano GB, Jori MC (2002) Efficacy and safety of amisulpride 50 mg versus paroxetine 20 mg in major depression: a randomized, double-blind, parallel group study. Int Clin Psychopharmacol 17:27-32.
18. Collaborative Working Group on Clinical Trials Evaluations (1998) Assessing the effects of atypical antipsychotics on negative symptoms. J Clin Psychiatry 59(Suppl. 12):28-34.
19. Cramer J, Rosenheck R, Xu W, Henderson W, Thomas J, Charney D (2001) Detecting improvement in quality of life and symptomatology in schizophrenia. Schizophr Bull 27:227-234.
20. Danion J-M, Rein W, Fleurot O and the Amisulpride Study Group (1999) Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Am J Psychiatry 156:610-616.
21. Davis JM, Chen N (2001) The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials. J Clin Psychiatry 62:757-771.
22. Fenton WS, McGlashan TH, Victor BJ, Blyler CR (1997) Symptoms, subtype, and suicidality in patients with schizophrenia spectrum disorders. Am J Psychiatry 154:199-204.
23. Freeman HL (1997) Amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia: three efficacy studies. Int Clin Psychopharmacol 12(Suppl. 2):11-17.
24. Geddes J, Mercer G, Frith CD, MacMillan F, Owens DG, Johnstone EC (1994) Prediction of outcome following a first episode of schizophrenia. A follow-up study of Northwick Park first episode study subjects. Br J Psychiatry 165:664-668.
25. Glaser T, Sommermeyer H, Faßbender M, Mauler F (1998) Das Rezeptorbindungsprofil von cis-Flupentixol. In: Flupentixol-Typisches oder A typisches Wirkspektrum? (Glaser T, Soyka M, eds.), Darmstadt: Steinkopff Verlag, pp. 9-21.
26. Goldman RS, Tandon R, Liberzon I, Greden JF (1992) Measurement of depression and negative symptoms in schizophrenia. Psychopathology 25:49-56.
27. 3 receptor. J Neural Transm 103:1163-1175.
28. Grube BS, Bilder RM, Goldman RS (1998) Meta-analysis of symptom factors in schizophrenia. Schizophr Res 31:113-120.
29. Gruber AJ, Cole JO (1991) Antidepressant effects of flupentixol. Pharmacotherapy 11:450-459.
30. 2 dopamine receptors. Br J Pharmacol 121:731-736.
31. Harrow M, Yonan CA, Sands JR, Marengo J (1994) Depression in schizophrenia: are neuroleptics, akinesia or anhedonia involved? Schizophr Bull 20:327-338.
32. Helmchen H, Hippius H (1967) Depressive syndrome im Verlauf neuroleptischer Therapie. Nervenarzt 38: 455-458.
33. Hietala J, Syvalahti E, Vilkman H, Vuorio K, Rakkolainen V, Bergman J, et al. (1999) Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia. Schizophr Res 35:41-50.
34. Hughes MA, Price RL, Marrs DW (1986) Linking theory construction and theory testing: models with multiple indicators of latent variables. Acad Management Rev 11:128-144.
35. Huppert JD, Weiss KA, Lim R, Pratt S, Smith TE (2001) Quality of life in schizophrenia: contributions of anxiety and depression. Schizophr Res 51:171-180.
36. Johnson DAW (1988) The significance of depression in the prediction of relapse in chronic schizophrenia. Br J Psychiatry 152:320-323.
37. Johnstone EC, Crow TJ, Frith CD, Carney MWP, Price JS (1978) Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet 1:848-851.
38. Joreskög KG, Sörbom D (1993) LISREL 7.20: User Reference Guide. Chicago, IL: Scientific Software International Inc.
39. Joyce JN, Goldsmith SG, Gurevich EV (1997) Limbic circuits and monoamine receptors: dissecting the effects of antipsychotics from disease processes. J Psychiatr Res 31:197-217.
40. 2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 155:921-928.
41. Kapur S, Seeman P (2001) Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry 158:360-369.
42. Keck P Jr, Buffenstein A, Ferguson J, Feighner J, Jaffe W, Harrigan EP, Morrissey MR (1998) Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology 140:173-184.
43. King DJ (1998) Drug treatment of the negative symptoms of schizophrenia. Eur Neuropsychopharmacol 8:33-42.
44. Koreen AR, Siris SG, Chakos M, Alvir J, Mayerhoff D, Lieberman J (1993) Depression in first-episode schizophrenia. Am J Psychiatry 150:1643-1648.
45. Lecrubier Y, Boyer P, Turjanski S, Rein W (1997) Amisulpride vs. imipramine and placebo in dysthymia and major depression. J Affect Dis 43:95-103.
46. Leucht S, Pitschel-Walz G, Engel RR, Kissling W (2002) Amisulpride, an unusual 'atypical' antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 159:180-190.
47. Leysen JE, Janssen PAJ, Schotte A, Luyten WHML, Megens AAHP (1993) Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5-HT2 receptors. Psychopharmacology 112:40-54.
48. Loas G, Boyer P, Legrand A (1996) Anhedonia and negative symptomatology in chronic schizophrenia. Compr Psychiatry 37:5-11.
49. Loas G, Noisette C, Legrand A, Boyer P (2000) Is anhedonia a specific dimension in chronic schizophrenia? Schizophr Bull 26:495-506.
50. Marder SR, Davis JM, Chouinard G (1997) The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 58:538-546.
51. Meltzer HY (2002) Action of atypical antipsychotics. Am J Psychiatry 159:153-154.
52. Meltzer HY, Okayli G (1995) Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 152:183-190.
53. Müller MJ, Wetzel H (1998) Dimensionality of depression in acute schizophrenia: a methodological study using the Bech-Rafaelsen Melancholia scale (BRMES). J Psychiatr Res 32:369-378.
54. Müller MJ, Benkert O (2000) Der Stellenwert von Amisulprid in der Behandlung von Patienten mit schizophrenen Erkrankungen-Ergebnisse kontrollierter Studien. In: Amisulprid. (Hippius H, ed.) München: Urban und Vogel, pp. 33-57.
55. Müller MJ, Wetzel H, Szegedi A, Benkert O (1999) Three dimensions of depression in patients with acute psychotic disorders: a replication study using the Bech-Rafaelsen Melancholia Scale. Compr Psychiatry 40:449-457.
56. Müller MJ, Szegedi A, Wetzel H, Benkert O (2001) Depressive factors and their relationships with other symptom domains in schizophrenia, schizoaffective disorder, and psychotic depression. Schizophr Bull 27:19-28.
57. Müller MJ, Wetzel H, Eich FX, Rein W, Puech A, Benkert O (2002) Dose-related effects of amisulpride on five dimensions of psychopathology in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol, in press.
58. Nyberg S, Nakashima Y, Nordström AL, Halldin C, Farde L (1996) Positron emission tomography of in-vivo binding characteristics of antipsychotic drugs. Br J Psychiatry 169(Suppl. 29):40-44.
59. Overall JE, Gorham DR (1962) The Brief Psychiatric Rating Scale. Psychol Rep 10:799-812.
60. 3 dopamine receptor antagonist activity and limbic selectivity. J Pharmacol Exp Ther 280:73-82.
61. Ravizza L (1999) Amisulpride in medium-term treatment of dysthymia: a six-month, double-blind safety study vs. amitriptyline. J Psychopharmacol 13:248-254.
62. Rein W, Turjanski S (1997) Clinical update on amisulpride in deficit schizophrenia. Int Clin Psychopharmacol 12(Suppl. 2): 19-27.
63. Roy A (1986) Depression, attempted suicide and suicide in patients with chronic schizophrenia. Psychiatr Clin North Am 9:193-206.
64. Saleem P, Olie JP, Loo H (2002) Social functioning and quality of life in the schizophrenic patient: advantages of amisulpride. Int Clin Psychopharmacol 17:1-8.
65. 3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 280:84-97.
66. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, et al. (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124:57-73.
67. Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, et al. (1995) Ziprasidone (CP 88059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 275:101-113.
68. Simpson GM, Angus JW (1970) A rating scale for extrapyramidal side effects. Acta Psychiat Scand 212:11-19.
69. Siris SG (1991) Diagnosis of secondary depression in schizophrenia: implications for DSM-IV. Schizophr Bull 17:75-98.
70. Smeraldi E (1998) Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: a double-blind comparative study. J Affect Dis 48:47-56.
71. Tanaka JS (1993) Multifaceted conceptions of fit in structural equation models. In: Testing Structural Equation Models. (Bollen KA, Long JS, eds.) Newbury Park, CA: Sage, pp. 10-39.
72. The Scottish Schizophrenia Research Group (1987) The Scottish First Episode Schizophrenia Study. II. Treatment: pimozide versus flupenthixol. Br J Psychiatry 150:334-338.
73. Tollefson GD, Sanger TM, Beasley CM, Tran PV (1998a) A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. Biol Psychiatry 43:803-810.
74. Tollefson GD, Sanger TM, Lu Y, Thieme ME (1998b) Depressive signs and symptoms in schizophrenia. A prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 55:250-258.
75. 2A receptors: a PET study of chlorpromazine, clozapine and amisulpride in schizophrenic patients. Am J Psychiatry 155:505-508.
76. van Putten T, Marder SR (1987) Behavioral toxicity of antipsychotic drugs. J Clin Psychiatry 48(Suppl.):13-19.
77. 2-like antagonist. Psychopharmacology 137:223-232.
78. Xiberas X, Martinot JL, Mallet L, Artiges E, Canal M, Loc'h C, et al. (2001) In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia. J Clin Psychopharmacol 21:207-221.